Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Lee, Jin Woo | - |
dc.contributor.author | Yoon, Ki Tae | - |
dc.contributor.author | Kim, Chang Wook | - |
dc.contributor.author | Park, Hana | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Paik, Soon Ku | - |
dc.contributor.author | Lee, Jung Il | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.date.accessioned | 2021-08-11T09:43:58Z | - |
dc.date.available | 2021-08-11T09:43:58Z | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 1542-3565 | - |
dc.identifier.issn | 1542-7714 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4514 | - |
dc.description.abstract | BACKGROUND & AIMS: There are no globally agreed upon treatment guidelines for patients with chronic hepatitis B virus (HBV) with multidrug resistance (MDR). We conducted a multicenter, prospective, real-world cohort study of effects of tenofovir disoproxyl fumarate (TDF) monotherapy and TDF-based combination therapy, as rescue therapy, in patients with multidrug-resistant chronic HBV infections. METHODS: We recruited patients with chronic HBV infection with resistance to antivirals from 8 tertiary hospitals in Korea. Patients (n=423) received rescue therapy with TDF monotherapy (n= 174) or TDF-based combination therapy (n=249). The median follow-up period was 180 weeks. A virologic response was defined as a serum HBV DNA level of <20 IU/mL. RESULTS: Cumulative rates of virologic response did not differ significantly between the groups that received TDF monotherapy vs combination therapy at 48 weeks (71.7% vs 68.9%), 96 weeks (85.1% vs 84.2%), 144 weeks (92.1% vs 92.7%), 192 weeks (93.4% vs 95.7%), or 240 weeks (97.7% vs 97.2%). Serum levels of HBV DNA below 4.0 log(10) IU/mL (odds ratio, 2.478; 95% CI 1.959-3.135; P < .001) and the absence of mutations associated with resistance to adefovir (odds ratio, 1.570; 95% CI 1.279-1.926; P < .001) were associated with virologic response in patients with MDR. There was no significant difference of virologic response among patients of different ages, sex, patients with vs without cirrhosis, positivity for hepatitis B e antigen, or renal function (all P > .05). CONCLUSION: In a multicenter, real-world cohort study, long-term use of TDF monotherapy showed non-inferior antiviral efficacy compared with that of TDF-based combination therapy in patients with MDR. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | W. B. Saunders Co., Ltd. | - |
dc.title | Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.cgh.2018.10.037 | - |
dc.identifier.scopusid | 2-s2.0-85065896258 | - |
dc.identifier.wosid | 000468432400028 | - |
dc.identifier.bibliographicCitation | Clinical Gastroenterology and Hepatology, v.17, no.7, pp 1348 - + | - |
dc.citation.title | Clinical Gastroenterology and Hepatology | - |
dc.citation.volume | 17 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1348 | - |
dc.citation.endPage | + | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-B | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | ADEFOVIR | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | NUCLEOSIDE | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | Hepatitis B | - |
dc.subject.keywordAuthor | Tenofovir | - |
dc.subject.keywordAuthor | Rescue Therapy | - |
dc.subject.keywordAuthor | Antiviral Resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.